Cobenfy also contains trospium, which blocks some of the side effects. The most common are nausea, vomiting and indigestion.
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...
Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the research Some people who took a new schizophrenia drug for a year ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...